Delving into the Latest Updates on Malaria vaccine(National Institute of Allergy & Infectious Diseases) with Synapse

Overview

Basic Info

Drug Type

Recombinant vector vaccine, Prophylactic vaccine

Synonyms

Malaria vaccine

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication

Malaria

Inactive Indication-

Originator Organization

National Institute of Allergy & Infectious Diseases

Active Organization

Crucell Holdings, Inc.

Program for Appropriate Technology in HealthNational Institute of Allergy & Infectious Diseases

+ [1]

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The overall goal of this study is to assess the impact of RTS,S (malaria) vaccination and PBO nets on malaria infection and transmission, independently and how they interact when they are introduced together.
The specific objectives for the study are as follows:
1. To estimate the impact of PBO nets and RTS,S vaccine on Plasmodium infection prevalence and transmission, independently and how they interact when they are introduced together in Malawi (Phase 1).
2. To assess the feasibility of evaluating the impact of RTS,S vaccine and PBO nets independently in a larger scale future study.

Start Date04 Feb 2020

Sponsor / Collaborator

Michigan State University

[+3]

EUCTR2019-002872-14-GB / Unknown statusPhase 1/2IIT

A Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium vivax malaria vaccine candidate PvDBPII in Matrix M1 in healthy adults living in the UK - VAC079: Safety and efficacy of the PvDBPII in Matrix M1 vaccine

Start Date12 Nov 2019

Sponsor / Collaborator-

100 Clinical Results associated with Malaria vaccine(National Institute of Allergy & Infectious Diseases)

Login to view more data

100 Translational Medicine associated with Malaria vaccine(National Institute of Allergy & Infectious Diseases)

Login to view more data

100 Patents (Medical) associated with Malaria vaccine(National Institute of Allergy & Infectious Diseases)

Login to view more data

150

Literatures (Medical) associated with Malaria vaccine(National Institute of Allergy & Infectious Diseases)

31 Dec 2024·Human Vaccines & Immunotherapeutics

A systematic review on malaria and dengue vaccines for the effective management of these mosquito borne diseases: Improving public health

Review

Author: Alanzi, Abeer ; Shrwani, Reem ; Albalawi, Reem ; Marghlani, Lujain ; Saad, Abrar ; Althobaiti, Khaled ; Al-Osaimi, Hind M. ; Alasmari, Saba ; Alsofiyani, Razan ; Al-Rowaili, Badria ; Alhulaili, Zainab ; Alqarni, Rawan ; Kanan, Mohammed

Insect vector-borne diseases (VBDs) pose significant global health challenges, particularly in tropical and subtropical regions. The WHO has launched the "Global Vector Control Response (GVCR) 2017-2030" to address these diseases, emphasizing a comprehensive approach to vector control. This systematic review investigates the potential of malaria and dengue vaccines in controlling mosquito-borne VBDs, aiming to alleviate disease burdens and enhance public health. Following PRISMA 2020 guidelines, the review incorporated 39 new studies out of 934 identified records. It encompasses various studies assessing malaria and dengue vaccines, emphasizing the significance of vaccination as a preventive measure. The findings indicate variations in vaccine efficacy, duration of protection, and safety considerations for each disease, influencing public health strategies. The review underscores the urgent need for vaccines to combat the increasing burden of VBDs like malaria and dengue, advocating for ongoing research and investment in vaccine development.

01 Dec 2024·Nature Reviews Microbiology

Malaria vaccines: a new era of prevention and control

Review

Author: Healy, Sara A ; Duffy, Patrick E ; Fried, Michal ; Gorres, J Patrick

Malaria killed over 600,000 people in 2022, a death toll that has not improved since 2015. Additionally, parasites and mosquitoes resistant to existing interventions are spreading across Africa and other regions. Vaccines offer hope to reduce the mortality burden: the first licensed malaria vaccines, RTS,S and R21, will be widely deployed in 2024 and should substantially reduce childhood deaths. In this Review, we provide an overview of the malaria problem and the Plasmodium parasite, then describe the RTS,S and R21 vaccines (the first vaccines for any human parasitic disease), summarizing their benefits and limitations. We explore next-generation vaccines designed using new knowledge of malaria pathogenesis and protective immunity, which incorporate antigens and platforms to elicit effective immune responses against different parasite stages in human or mosquito hosts. We describe a decision-making process that prioritizes malaria vaccine candidates for development in a resource-constrained environment. Future vaccines might improve upon the protective efficacy of RTS,S or R21 for children, or address the wider malaria scourge by preventing pregnancy malaria, reducing the burden of Plasmodium vivax or accelerating malaria elimination.

01 Dec 2024·Vaccine

RTS, S malaria vaccination among children aged 24–59 months in the Sunyani Municipality, Ghana; 2023

Article

Author: Kubio, Chrysantus ; Tamal, Christopher Sunkwa ; Adjei, Michael Rockson ; Kyeremeh, Richard Adinkrah ; Ziema, Sorengmen Amos ; Abanga, Williams Azumah ; Zacharia, Mansulu Mohammed

BACKGROUNDFollowing the successful pilot of RTS,S malaria vaccine, it has been recommended by the WHO for prevention of Plasmodium falciparum malaria in children living in endemic areas. Despite the proven benefits of the malaria vaccine, uptake especially of the fourth dose, remains relatively low. We assessed complete uptake of RTS,S malaria vaccine among children 24-59 months and associated factors in the Sunyani Municipality of Ghana.METHODSA cross-sectional study was conducted among 361 caregivers of children aged 24-59 months in the Sunyani Municipality, who had received at least one dose of RTS,S malaria vaccine. Structured questionnaires were administered to caregivers and relevant vaccination information was extracted from the maternal and child health record books. Binary logistic regression analysis was used to determine factors associated with complete uptake of the vaccine at 95 % confidence interval (CI).RESULTSApproximately 45 % (164/361) of the children had completed the RTS,S malaria vaccination schedule. Children aged 48-59 months (AOR:0.26, 95 %CI:0.09-0.76), those with caregivers who believed that children were being used for experiment (AOR:0.29, 95 %CI:0.16-0.54) or doubted the safety of the vaccine (AOR:0.27, 95 %CI:0.14-0.52) were less likely to complete the four doses. On the other hand, children of caregivers who reported vaccine shortages and travelled long distances to access immunization services (AOR:3.15, 95 %CI:1.17-8.47), and those with adequate knowledge on the malaria vaccine (AOR:1.89, 95 %CI:1.08-3.29) were more likely to complete the vaccination schedule.CONCLUSIONLess than half of the children who started RTS,S malaria vaccination completed the full schedule. Age of child, caregiver knowledge and perception of the malaria vaccine, and access to immunization service were associated with complete uptake of the RTS,S malaria vaccine. Strengthening caregiver education and access to immunization services could improve uptake of the subsequent doses and coverage of the fourth dose.

100 Deals associated with Malaria vaccine(National Institute of Allergy & Infectious Diseases)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Malaria vaccine(National Institute of Allergy & Infectious Diseases)	-	-

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Malaria	Phase 1	-	National Institute of Allergy & Infectious Diseases	-
Malaria	Phase 1	-	Program for Appropriate Technology in Health	-
Malaria	Phase 1	-	Novavax, Inc.	-
Malaria	Phase 1	-	Crucell Holdings, Inc.	-